Icon

PENBRITIN-S (nda050072)- (EQ 125MG BASE/VIAL,EQ 250MG BASE/VIAL,EQ 500MG BASE/VIAL,EQ 1GM BASE/VIAL,EQ 2GM BASE/VIAL,EQ 4GM BASE/VIAL)

AMPICILLIN SODIUM WYETH AYERST
EQ 125MG BASE/VIAL,EQ 250MG BASE/VIAL,EQ 500MG BASE/VIAL,EQ 1GM BASE/VIAL,EQ 2GM BASE/VIAL,EQ 4GM BASE/VIAL
No No
Expired Expired
None None
None No
PENBRITIN-S for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: *Respiratory tract Infections caused by S. pneumoniae (formerly D. pneumoniae). Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic Streptococci. *Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria (Listeria monocytogenes, N. meningitidis). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. *Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus sp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella sp. respond to ampicillin. *Urinary Tract Infections caused by sensitve strains of E. coli and Proteus mirabilis. *Gastrointestinal Infections caused by Salmonella typhosa (typhoid fever), other Salmonella sp., and Shigella sp. (dysentery) usually respond to oral or intravenous therapy.
8 0 6
Total Other Developers None
Drugs with Suitability Yes
EQ 125MG BASE/VIAL ** ** - - -
EQ 250MG BASE/VIAL ** ** - - -
EQ 500MG BASE/VIAL ** ** - - -
EQ 1GM BASE/VIAL ** ** - - -
EQ 2GM BASE/VIAL ** ** - - 7
EQ 4GM BASE/VIAL ** ** - - -
NDA Sales Available Total Generic Sales Available
No 6
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ****** ****** **** *********** **************** **, ***********, ***** *-****, ******* (***) ***
****** ******** *** *** *** ******** ********** ******** ******** ********* *********** *** ********** *, *******, ****** *****, ***** (***) ***
****** ***** ****** ******* ********* ****** ******* *********** ****-***, **.**.***, **********, ********** ******, *******-********** ********, *******, ********* ******, ***** (***) ***
****** ***** ****** ******* ***** *** ******* ******* *********** ** **: *** ** ***, *** ** ***, *** ** ***, *** ** ***, *****, ***, **** **: *-*/*, *-* & *-*, ********* *******, ********* ******, ************, ********* ******, ***** (***) ***
****** ****** ****** *** ****** ********* ******* ******* *********** ***, *.*.*.*., *********, ********, ******* ******, ***** (***) ***
****** ************ ***** *.*.*. *********** *** **** ******** ********** **, *******, *****, ***** (***) ***
****** ************ ************ *********** ******* ******* *********** **** ****** ********, ***/* & ***/**, *************, ***********, ************ ****,, *********, ********* ******, ***** (***) ***
****** ******** *** *** *** ******** ********** ******** ******** ********* *********** *** ********** *, *******, ****** *****, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.